GLPBio

Apoptosis

Read More about this category

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

 

References:

1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.

2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.

3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.

4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.

5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

Research Areas

Products Related to Apoptosis(3394)

  • GC73243 structure
    GC73243Nrf2-IN-3
    CAS: 6325-13-9
    Purity: >99.00%

    Nrf2-IN-3 (Verbindung R16) ist ein Nrf2-Hemmer.

  • GC73268 structure
    GC73268PH14
    Purity: >99.00%

    PH14 ist ein dualer PI3K/HDAC-Inhibitor mit IC50-Werten von 20,3 nM und 24,5 nM für PI3Kα bzw. HDAC3.

  • GC73269 structure
    GC73269ABBV-467
    CAS: 2287186-66-5
    Purity: >99.00%

    ABBV-467 ist ein selektiver MCL-1-Inhibitor (Ki: <0,01 nM).

  • GC73272 structure
    GC73272PARP-1-IN-3
    CAS: 2976342-33-1
    Purity: >99.00%

    PARP-1-IN-3, ein Benzamidderivat, ist ein potenter PARP-1 Inhibitor mit IC50 Werten von 0,25 nM und 2,34 nM für PARP-1 bzw. PARP-2.

  • GC73274 structure
    GC73274EGFR T790M/L858R-IN-2
    CAS: 2955607-40-4
    Purity: >99.00%

    EGFR T790M/L858R-IN-2 ist ein potenter und selektiver EGFRT790M/L858R-Inhibitor mit IC50-Werten von 3,5, 1290 nM für EGFRT790M/L858R bzw. EGFR WT.

  • GC73275 structure
    GC73275PD-L1-IN-2
    CAS: 2894733-91-4
    Purity: >98.00%

    PD-L1-IN-2 ist ein potenzieller Tumorimmunagent, der PD-L1 hemmt.

  • GC73288 structure
    GC73288CDK8-IN-13
    CAS: 918523-75-8
    Purity: >98.00%

    CDK8-IN-13 ist ein potenter, selektiver und oral aktiver CDK8-Inhibitor mit einem IC50-Wert von 51,9 nM.

  • GC73294 structure
    GC73294F5446
    CAS: 2304465-89-0
    Purity: >99.00%

    F5446 (Compound 1) ist ein selektiver kleinmolekularer Inhibitor der SUV39H1 Metltransferase.

  • GC73309 structure
    GC73309Anti-melanoma agent 1
    CAS: 2418579-17-4
    Purity: >99.00%

    Anti-melanoma agent 1 (Verbindung 5m) ist ein Anti-Melanom-Mittel und induziert Zellapoptose.

  • GC73311 structure
    GC73311STAT3-IN-13
    CAS: 2248552-86-3
    Purity: >99.00%

    STAT3-IN-13 (Verbindung 6f) ist ein starker STAT3-Hemmer.

  • GC73313 structure
    GC73313PI3Kα-IN-9
    CAS: 2715287-67-3
    Purity: >99.00%

    PI3Kα-IN-9 (Verbindung 27) ist ein selektiver, langwirkender und oral aktiver PI3Kα-Inhibitor mit IC50-Werten von 4,4, 128, 146 und 153 nM für PI3Kα, PI3Kγ, PI3Kδ und PI3Kβ.

  • GC73317 structure
    GC73317ODN 1585 sodium
    Purity: >93.00%

    ODN 1585 sodium ist ein starker Induktor der IFN- und TNFα-Produktion.

  • GC73331 structure
    GC73331BMS-37
    CAS: 1675202-20-6
    Purity: >98.00%

    BMS-37 ist ein PD-1/PD-L1 Immunkontrollpunkt-Inhibitor.

  • GC73355 structure
    GC73355STAT3-SH2 domain inhibitor 1
    CAS: 2816059-41-1
    Purity: >98.50%

    STAT3-SH2 domain inhibitor 1 ist ein potenter Src Homology 2 (SH2) Domain of STAT3 (STAT3-SH2 Domain) Inhibitor mit einem Kd Wert von 1,57 μM.

  • GC73371 structure
    GC73371Enpp/Carbonic anhydrase-IN-2
    CAS: 2883495-39-2
    Purity: >99.00%

    Enpp/Carbonic anhydrase-IN-2 ist ein potenter Enpp- und Carbonandrase-Inhibitor mit IC50s von 1.13, 1.07, 0.74, 0.33, 0.68 für NPP1, NPP2, NPP3, CA-IX, CA-XII.

  • GC73372 structure
    GC73372(S)-Sabutoclax
    CAS: 1228178-73-1
    Purity: >98.00%

    (S)-Sabutoclax S-BI-97C1, ein optisch reines Apogossypolderivat, ist ein pan-aktiver Inhibitor von antiapoptotischen B-Zell-Lymphom/Leukämie-2 Bcl-2 Proteinen.

  • GC73374 structure
    GC73374TD1092
    Purity: >99.00%

    TD1092 ist ein pan-IAP-Abbau, der cIAP1, cIAP2 und XIAP abbaut.

  • GC73396 structure
    GC73396PRMT6-IN-3
    CAS: 2890765-10-1
    Purity: >99.00%

    PRMT6-IN-3 (Verbindung 25) ist ein selektiver PRMT6-Inhibitor mit einem IC50-Wert von 192 nM.

  • GC73417 structure
    GC73417CASP8-IN-1
    CAS: 1956368-39-0
    Purity: >98.00%

    CASP8-IN-1 (Verbindung 63-R) ist ein selektiver Inhibitor für Caspase 8 (CASP8), mit einem IC50 von 0,7 μM.

  • GC73424 structure
    GC73424PRT062607 acetate
    CAS: 1370261-98-5
    Purity: >99.00%

    PRT062607 acetate ist ein oral verfügbarer Syk-Hemmer (IC50: 1 nM), der Entzündungen und Induktionsapoptose hemmt.

  • GC73428 structure
    GC73428CWI1-2 hydrochloride
    CAS: 2408590-37-2
    Purity: >98.00%

    CWI1-2 hydrochloride ist ein IGF2BP2-Inhibitor, der IGF2BP2 bindet und seine Interaktion mit m6A-modifizierten Zieltranskripten hemmt, Apoptose und Differenzierung induziert.

  • GC73441 structure
    GC73441EAPB 02303
    CAS: 1958290-51-1
    Purity: >99.00%

    EAPB 02303 ist ein Mikrotubuli-störender Wirkstoff und Hemmer.

  • GC73469 structure
    GC73469Cereblon inhibitor 2
    CAS: 2639380-62-2
    Purity: >98.00%

    Cereblon inhibitor 2 (Verbindung 8) ist ein Cereblon-Inhibitor, der in der soliden Tumorforschung, insbesondere Brustkrebs, nützlich ist.

  • GC73476 structure
    GC73476MYC-RIBOTAC
    Purity: >98.00%

    MYC-RIBOTAC ist eine Ribonuklease-Targeting Chimäre (RIBOTAC) zu MYC internal ribosome entry site (IRES).